{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_16132", "batch_size": 200, "batch_pos": 93, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment uses neutral language without high-potency verbs, metaphors, or intensifiers.", "method": "llm_batch", "batch_id": "batch_2_18536", "batch_size": 200, "batch_pos": 61, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment contains no moderate verbs paired with scale or impact information.", "method": "llm_batch", "batch_id": "batch_3_16208", "batch_size": 200, "batch_pos": 198, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "No loaded rhetorical question designed to imply alarm.", "method": "llm_batch", "batch_id": "batch_4_13736", "batch_size": 200, "batch_pos": 192, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "Reports advantages of technology; no explicit calming cue.", "method": "llm_batch", "batch_id": "batch_5_1072", "batch_size": 200, "batch_pos": 187, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "Segment does not contain a minimiser + scale contrast.", "method": "llm_batch", "batch_id": "batch_6_8312", "batch_size": 200, "batch_pos": 132, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "Segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_17044", "batch_size": 200, "batch_pos": 102, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "Describes capability/technology advantage: 'mRNA vaccine technology offers advantages'.", "method": "llm_batch", "batch_id": "batch_8_6648", "batch_size": 200, "batch_pos": 118, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
